9-15 January 2016
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Fingolimod in real life study reflects trial results
A study of 105 people taking fingolimod (Gilenya) at a Swiss clinic found that over a year the annual relapse rate was reduced by 44%, and 38% showed no disease activity (no relapse, no new lesions, EDSS stable). Side effect frequency was similar to that reported in the trials.
Source: MS News Today
MS Trust link: Fingolimod (Gilenya)